Attached files
file | filename |
---|---|
8-K/A - 8-K/A - Zymeworks Inc. | d52397d8ka.htm |
Exhibit 99.1
Zymeworks to Present at Upcoming Investor Conferences
Vancouver, Canada (September 3, 2020) Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences.
| Wells Fargos 2020 Healthcare Conference is scheduled for September 9-10, 2020. Zymeworks is presenting on Wednesday, September 9, 2020 at 11:20 a.m. ET. |
| Citis 15th Annual BioPharma Conference is scheduled for September 9-10, 2020. |
| H.C. Wainwrights 22nd Annual Global Investment Conference is scheduled for September 14-16, 2020. Zymeworks is presenting on Tuesday, September 15, 2020 at 2:30 p.m. ET. |
Interested parties can access a live webcast of the presentations via a link from Zymeworks website at http://ir.zymeworks.com/events-and-presentations, which will also host recorded replays available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks proprietary ZymeLink linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.
Contacts:
Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com
Tiffany Tolmie
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Kavita Shah, Ph.D.
(604) 678-1388
media@zymeworks.com